ICPE conference
Gillian Hall
-
Register
- Non-Members - Free!
- Members - Free!
An interview with Gillian Hall, PhD, FISPE
Time | Topic |
0:11 | Please provide a brief overview of your career and current position |
| Independent epidemiologist, in drug safety epidemiology- post-authorization safety studies. |
0:25 | Can you comment on the first ISPE meeting you attended? |
| In Minneapolis- mid-80s. |
0:40 | What was the atmosphere like at the first ICPE? |
| Excited environment, people felt like they were responding to a growing need. |
1:07 | What do you think was missing from the early meetings? |
| Everything we see today- methods, data sources, procedures, communications between regulators academics and industry. |
1:27 | Can you comment on the ISPE Anaheim meeting? |
| First meeting with a formal board. Workhorse meetings- science beginning to evolve. |
2:06 | How was the first board selected? |
| No election- call from the podium for volunteers. |
2:43 | Who were the attendees at the Anaheim meeting? |
| World wasn’t well represented- US mainly, and Europe; makeup was more industry and regulatory, and less academic. |
3:15 | What are your fondest memories of the early ISPE meetings? |
| Very friendly, encompassing society, positive attitude of inclusion. |
4:07 | Can you comment on the social aspects of ISPE? |
| Joined as the youngest member- but was socializing with people much more senior in the field. People are close friends even though they meet only twice a year. |
5:01 | When did you first get involved with pharmacoepi? |
| Two major drug adverse event incidents- practolol, and benoxaprofen. Needed to set up a system to detect problems not detected at the clinical trials stage, that’s the stage when began this work. |
6:23 | What ISPE activities were you involved in early on? |
| On the membership committee, getting involved in the UK to spread the word. Development of Pharmacoepi and Drug Safety Journal. |
7:08 | What do you feel is ISPE’s greatest impact on the field? |
| Forum where everybody involved in the field can come together. |
7:40 | What do you see as the future of ISPE? |
| Future of ISPE will reflect future of pharmacoepi. Issue will be getting parts of the world involved who haven’t been. |
7:56 | What wisdom would you like to pass to future leaders and members of ISPE? |
| New board members should look forward, not backwards. Keep the open personality of the society, will allow it to continue to grow. |
8:41 | What areas do you see where ISPE can grow? |
| Biologicals, devices are a new field. |
9:27 | What were those early ICPE meetings like? |
| Small, compact, homely. People knew each other well. |
10:41 | Can you tell us about the early European ICPE meetings? |
| ISPE is an international society, and needed to have representation of non-US membership, of Europe. |
11:35 | How has ISPE evolved over the years? |
| The huge development, jump in terms of the methods and procedures that we have for drug safety. |
12:21 | Who were some of your key mentors during the early years? |
| Not one key mentor- everyone was coming together, everyone working for a goal, it felt like a joint effort. |
13:08 | How has ISPE impacted you personally and professionally? |
| Society has helped me keep contacts, stay on track. |
With support from Epi Excellence LLC.